TNFSF13 (Human) ELISA Kit
* The price is valid only in USA. Please select country.
-
More Files
- More Functions
-
Specification
Product Description
TNFSF13 (Human) ELISA Kit is a sandwich enzyme immunoassay for the quantitative measurement of human TNFSF13.
Suitable Sample
Cell Culture Supernate, Cell Lysates, Plasma (EDTA, Heparin), Serum
Sample Volume
100 uL
Label
HRP-conjugated
Detection Method
Colorimetric
Assay Type
Quantitative
Calibration Range
156 to 10000 pg/mL
Reactivity
Human
Regulation Status
For research use only (RUO)
Storage Instruction
Store at 4°C for 6 months, at -20°C for 12 months. Avoid multiple freeze-thaw cycles.
-
Applications
Quantification
-
Gene Info — TNFSF13
Entrez GeneID
8741Gene Name
TNFSF13
Gene Alias
APRIL, CD256, TALL2, TRDL-1, UNQ383/PRO715, ligand
Gene Description
tumor necrosis factor (ligand) superfamily, member 13
Omim ID
604472Gene Ontology
HyperlinkGene Summary
The protein encoded by this gene is a member of the tumor necrosis factor (TNF) ligand family. This protein is a ligand for TNFRSF17/BCMA, a member of the TNF receptor family. This protein and its receptor are both found to be important for B cell development. In vitro experiments suggested that this protein may be able to induce apoptosis through its interaction with other TNF receptor family proteins such as TNFRSF6/FAS and TNFRSF14/HVEM. Three alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported. Other transcripts that skip the last exon of the upstream gene (TNFSF12) and continue with the second exon of this gene have been identified; such read-through transcripts are contained in GeneID 407977, TNFSF12-TNFSF13. [provided by RefSeq
Other Designations
OTTHUMP00000174780|TNF- and APOL-related leukocyte expressed ligand 2|a proliferation inducing ligand|tumor necrosis factor (ligand) superfamily member 13 transcript variant delta|tumor necrosis factor ligand superfamily member 13 epsilon|tumor necrosis f
-
Interactome
-
Pathway
-
Disease
-
Publication Reference
-
Elevated serum level of B-cell activating factor (BAFF) after rituximab therapy in pemphigus vulgaris patients suggests a possible therapeutic efficacy of B-cell depletion therapies combined with anti-BAFF agents.
Elham Daneshvar, Soheil Tavakolpour, Hamidreza Mahmoudi, Maryam Daneshpazhooh, Amir Teimourpour, Saeed Aslani, Kamran Balighi.
International Journal of Dermatology 2023 Apr; 62(4):567.
Application:Quant, Human, Human serum.
-
Elevated serum level of B-cell activating factor (BAFF) after rituximab therapy in pemphigus vulgaris patients suggests a possible therapeutic efficacy of B-cell depletion therapies combined with anti-BAFF agents.
- +1-909-264-1399
+1-909-992-0619
Toll Free : +1-877-853-6098 - +1-909-992-3401
- sales@abnova.com